A groundbreaking HIV prevention treatment in the form of a twice-yearly injection has shown promise in clinical trials, offering a potential alternative to daily medications for at-risk individuals. Lenacapavir, developed as a long-acting antiretroviral, could simplify prevention efforts by reducing the need for consistent oral therapy. However, experts warn that access will likely be limited, raising concerns about equity in global health responses. The treatment’s approval and distribution may hinge on cost, availability, and eligibility criteria, leaving many questions unanswered about its real-world impact.
Lenacapavir, a twice-a-year injection could transform HIV prevention, but it will not be available to all.
